New in Clinical Infectious Diseases -- from 2007-2019, Medicaid spending on ART⬆️ by 178%, driven by increased use (arguably a good thing) and higher prices (not a good thing) for newer treatments. doi.org/10.1093/cid/ci… Benjamin Rome, MD MPH BWH Pharmacoepidemiology & Pharmacoeconomics

would be a dream come true, not gonna lie

Great update on cutting edge treatment of NTM by Chuck Daley from National Jewish Health. Fascinating to hear about novel approaches, such as dual beta lactam Rx for M abscessus (imi + ceftaroline). #IDWeek2022

Novel c diff treatment, ibezapolstat. Non-systemic, favorable effect on bile acids and microbiome, may reduce risk of recurrence. Data presented just before SER-109 (further along, recent pubs in NEJM and JAMA) -- very promising approaches to a tough clinical problem.

Cefepime -- already exceptionally broad -- is being augmented (no pun intended) with novel beta lactamase inhibitors. Here taniborbactam; also enmetazobactam, as recently published in JAMA.

Interesting to see a drug in development for *uncomplicated* UTI. Comparator arm nitrofurantoin.

NTM pulmonary infection (esp macrolide-resistant) is huge unmet need in clinical ID -- great to see drug development proceeding in this area. Here's hoping epetraborole succeeds.

Want to deeply thank Mati Hlatshwayo Davis, MD, MPH David Leonhardt Baruch Fischhoff ProfEmilyOster and Carlos del Rio for joining us at IDWeek, and providing such thoughtful commentary on how to communicate about tough topics during this pandemic. 👏👏👏

Mask and vaccine mandates? Check. Socializing and networking over meals and drinks? Check. Some thoughts about this uncomfortable paradox here.
Big In-Person Medical Meetings and Cognitive Dissonance for ID Docs blogs.jwatch.org/hiv-id-observa… Priya Nori MD, FSHEA, FIDSA

Just in time for IDWeek -- Important study on changing demographics among speakers at after IDWeek Program Committee was charged with ensuring gender equity in speaker sessions.

Lesson: Intentional effort can lead to big-time changes.
doi.org/10.1093/cid/ci…

Some of the very best, most insightful and observant writing on life during the pandemic is in this latest book by David Sedaris.

Not surprisingly, it's incredibly funny -- and quite moving, too. littlebrown.com/titles/david-s… Little, Brown and Co

Monoclonal antibody approach to covid therapy =

Check out the display of recently published papers on the home page on Clinical Infectious Diseases -- we're trying to make it easier to view new content and highlights.
Includes author-written short summaries, and papers highlighted at 'Editor's Choice'. academic.oup.com/cid

Some further thoughts about the PANORAMIC molnupiravir trial results, which are fascinating -- even with a negative primary endpoint. Looking forward to seeing more.

Molnupiravir Results in PANORAMIC Study — It’s Not All Bad News blogs.jwatch.org/hiv-id-observa…

Hi #IDTwitter -- in the PANORAMIC study, anyone understand why the cited time to recovery data is both 6 days (15 minus 9) and 4.2 days? Which is it?Thank you ... papers.ssrn.com/sol3/papers.cf…

For those of you still watching football (the brutal American version), I'm afraid this gets it right. Thanks Will Leitch for articulating it so clearly. nymag.com/intelligencer/…

Molnupiravir vs standard of care for outpts with Covid19. No difference in the already low rate of hosp/death, but take a look at this Time to Recovery 2ndary endpoint, a 4-day benefit! Robust across subgroups. Caveat: Open label design. papers.ssrn.com/sol3/papers.cf… h/t Andrew Morris